Crystalvue Medical Corporation (6527.TWO) Stock
Crystalvue Medical Corporation

Company profile
Crystalvue Medical reported revenue of 949.05 million TWD for fiscal year 2025, up 9.3% from fiscal year 2024, and net income of 146.98 million TWD. That is a net profit margin of 15.5% for fiscal year 2025. Our analysis of its filings shows revenue growing from 823.96 million TWD in fiscal year 2023 to 949.05 million TWD in fiscal year 2025, 7.3% a year on average.
What stands out
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Crystalvue Medical Corporation
Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies. The company was founded in 2009 and is based in Taoyuan City, Taiwan.
Leadership
- Zhong Ping Zhuang — GM & Director
How much revenue does Crystalvue Medical make?
Crystalvue Medical reported 949.05 million TWD in revenue for fiscal year 2025, up 9.3% from 868.03 million TWD in fiscal year 2024.
What companies are similar to Crystalvue Medical?
Listed companies of a similar size in the same industry (targeted healthcare equipment) include St.Shine Optical Co.,Ltd. (1565.TWO), Icares Medicus, Inc. (6612.TWO), Medimaging Integrated Solution Inc. (6796.TW), Taiwan Biomaterial Co., Ltd. (6649.TWO).
How has Crystalvue Medical's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 721.61 million TWD; FY2022, 795.46 million TWD; FY2023, 823.96 million TWD; FY2024, 868.03 million TWD; FY2025, 949.05 million TWD.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Crystalvue Medical Corporation (6527.TWO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/6527.TWO